Genmab has gone from specialist biotech to front-page story after three cancer drugs cleared key Phase 3 hurdles and the stock price doubled in just three months. That kind of sudden spotlight often leaves some investors overexposed while others are still on the sidelines. This piece looks at how that news ripples through our Innovative Oncology Biotech Stocks screener and reveals three stocks most exposed to the same powerful catalyst.

The stocks highlighted below are just a starter set. The full screen surfaced 16 more oncology focused biotechs with equally compelling stories that are not covered here. To identify, compare, and analyze the highest conviction ideas from this group, head straight to the Innovative…